NervGen rises as TD Cowen issues new BUY on lead asset

Shares of NervGen Pharma (NGEN) traded higher on Thursday after TD Cowen initiated the Canadian biotech with a Buy recommendation, assuming $1.1B peak sales for the company’s lead asset NVG-291. The ...

NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68

NervGen Pharma (NGEN) has announced pricing of a public offering of 24M common shares, priced at $2.50 each, along with warrants to purchase the same number of shares at an exercise price of US$3.68.
Business Insider

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class ...
Nasdaq

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for ...
Business Insider

NervGen Announces Proposed Public Offering of Securities

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class ...
Yahoo Finance

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results

Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort ...
Yahoo Finance

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NervGen Pharma Corp.

View NervGen Pharma Corp. NGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.
Business Wire

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case ...

The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset There is currently no ...